Chugai Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,109,658	1,077,803	997,901	974,493	1,039,247	802,836
Other Revenue	181,571	180,138	172,710	136,874	220,699	196,923
Revenue	1,291,229	1,257,941	1,170,611	1,111,367	1,259,946	999,759
Revenue Growth (YoY)	5.66%	7.46%	5.33%	-11.79%	26.02%	27.04%
Cost of Revenue	368,657	363,690	339,409	413,306	476,251	338,147
Gross Profit	922,572	894,251	831,202	698,061	783,695	661,612
Selling, General & Admin	122,125	116,461	110,098	112,580	100,760	102,416
Research & Development	188,558	187,598	181,440	174,868	149,626	137,299
Other Operating Expenses	-351	-8,641	-2,339	-28,561	-	-
Operating Expenses	310,332	295,418	289,199	258,887	250,386	239,715
Operating Income	612,240	598,833	542,003	439,174	533,309	421,897
Interest Expense	-207	-207	5	-27	-61	-48
Interest & Investment Income	-	-	1,027	4,674	52	-
Other Non Operating Income (Expenses)	1,433	-820	-1	-	-2,134	-2,464
Pretax Income	622,174	597,806	543,034	443,821	531,166	419,385
Income Tax Expense	169,978	163,794	155,717	118,349	156,737	116,390
Earnings From Continuing Operations	452,196	434,012	387,317	325,472	374,429	302,995
Net Income	452,196	434,012	387,317	325,472	374,429	302,995
Net Income to Common	452,196	434,012	387,317	325,472	374,429	302,995
Net Income Growth	10.25%	12.06%	19.00%	-13.08%	23.58%	41.10%
Shares Outstanding (Basic)	1,646	1,646	1,645	1,645	1,645	1,644
Shares Outstanding (Diluted)	1,646	1,646	1,646	1,645	1,645	1,645
Shares Change (YoY)	0.00%	0.01%	0.01%	0.01%	0.01%	0.01%
EPS (Basic)	274.77	263.73	235.39	197.83	227.64	184.29
EPS (Diluted)	274.77	263.72	235.36	197.80	227.57	184.17
EPS Growth	10.25%	12.05%	18.99%	-13.08%	23.57%	41.09%
Free Cash Flow	374,774	310,007	397,185	337,977	181,487	213,657
Free Cash Flow Per Share	227.73	188.37	241.36	205.40	110.30	129.87
Dividend Per Share	122.000	122.000	98.000	80.000	78.000	76.000
Dividend Growth	24.49%	24.49%	22.50%	2.56%	2.63%	38.18%
Gross Margin	71.45%	71.09%	71.01%	62.81%	62.20%	66.18%
Operating Margin	47.41%	47.60%	46.30%	39.52%	42.33%	42.20%
Profit Margin	35.02%	34.50%	33.09%	29.29%	29.72%	30.31%
Free Cash Flow Margin	29.03%	24.64%	33.93%	30.41%	14.40%	21.37%
EBITDA	638,876	631,368	573,668	470,914	564,743	452,765
EBITDA Margin	49.48%	50.19%	49.01%	42.37%	44.82%	45.29%
D&A For EBITDA	26,636	32,535	31,665	31,740	31,434	30,868
EBIT	612,240	598,833	542,003	439,174	533,309	421,897
EBIT Margin	47.41%	47.60%	46.30%	39.52%	42.33%	42.20%
Effective Tax Rate	27.32%	27.40%	28.68%	26.67%	29.51%	27.75%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.